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In the current era, because of the prevalence of sonography, renal cell carcinoma usually can be detected
in the early stages and a huge tumor is rarely encountered. Recently, we found a huge clear cell-type
renal cell carcinoma that weighed approximately 2.7 kg, which is very rare.
Copyright  2013, Taiwan Urological Association. Published by Elsevier Taiwan LLC.1. Introduction
Renal cell carcinomas account for approximately 80e85% of
primary renal tumors and are the most common form of malignant
renal tumor. Because of the prevalence of sonography, renal tumors
usually can be detected at an early stage. A renal tumor with a
diameter >20 cm is extremely rare. Herein, we report a huge renal
cell carcinoma with a diameter of approximately 22 cm and
weighing 2.7 kg.
2. Case report
A 48-year-old male with no underlying disease experienced
progressive abdominal uplift for 8 months. He alsomentioned body
weight loss of approximately 20 kg over the past 2 years and gross
hematuria several times. However, no ﬂank pain, abdominal pain,
nausea, vomiting, or bowel habit changes were reported by the
patient. A physical examination found a signiﬁcantly palpable and
mild tender mass in the left upper quadrant of the abdomen. There
was no superﬁcial lymphadenopathy. Results of a laboratory ex-
amination showed the following levels of measurements: hemo-
globin, 5.0 g/dL; platelets, 608,000/mL; and alkaline phosphate,
252 IU/L. Other laboratory data were within normal limits. An
enhanced computed tomography (CT) scan (Fig. 1) revealed a hugeaohsiung Municipal Ta-Tung
hsiung City 80145, Taiwan.
ciation. Published by Elsevier Taiwtumor lesion (approximately 21.6  16.9  13.5 cm) with hetero-
geneous enhancement and some calciﬁed contents in the left
abdomen. No normal renal parenchyma was observed in the left
kidney, and the left renal vein was extremely engorged with
thrombi internally. There were lots of engorged, tortuous veins
around the tumor. Multiple hepatic and pulmonary metastatic le-
sions with central necrosis were also noted.
Under general anesthesia, he received a successful left radical
nephrectomy. During the operation, we found an engorged renal
vein of almost 4 cm in diameter internally ﬁlled with thrombi
(Fig. 2). In addition, there were extremely engorged vessels around
the tumor (Fig. 3). The entire tumor with the left kidney was
removed en bloc, and there was profound bleeding while we
attempted to dissect it. Multiple lymphadenopathies were found
during the operation, which were unresectable because of severe
adhesion to the aorta. The total blood loss was approximately
8000 mL. The postoperative tumor size was 22  17  14 cm, and it
weighed 2695 g (Fig. 4). Grossly, the cut surface revealed an ill-
deﬁned, yellowish, solid mass with multifocal necrosis and hem-
orrhaging. The tumor extended into the perirenal fat and renal vein,
and the pathological stage was pT3a. The histopathological diag-
nosis was clear cell-type renal cell carcinoma with Grade 2 Fuhr-
man nuclear grading. Laboratory data revealed that the lactate
dehydrogenase level was 1410 IU/L and that of calcium ions was
4.2 mg/dL. After the operation, he began targeted therapy with
sunitinib. However, the follow-up abdominal CT scan showed rapid
growth of metastatic cancer. The patient died 6 months after the
operation.an LLC. Open access under CC BY-NC-ND license.
Fig. 1. A huge heterogeneous enhanced tumor lesion in the left abdomen. Liver and
lung metastases were also noted.
Fig. 3. Engorged vessels around the huge tumor.
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Renal cell carcinoma arises from the renal parenchyma. It ac-
counts for approximately 2e3% of all adult malignant neoplasms.
The main symptoms are ﬂank pain, gross hematuria, and a palpable
abdominal massdthe “classic triad.” However, these symptoms
usually indicate advanced renal cell carcinoma. Recently, because of
the use of ultrasonography and CT, asymptomatic renal cell carci-
noma can be detected much earlier than before. Volpe et al indi-
cated an incidental detection rate of approximately 48e66%, which
was only approximately 7e13% in the 1970s.1 In addition, the size of
detected renal cell carcinomas is smaller, and the stage is lower.
More renal tumors are incidentally diagnosed and remain asymp-
tomatic.2e5
Many reports found that renal cell carcinomas grow slowly at
about 0.06e0.39 cm annually.1,6,7 Because of the slow growth rate,
metastasis may occur during the long period over which a tumor
becomes huge. Some reports indicated that tumor size plays an
important role in the prognosis. Kunkle et al stated that the met-
astatic disease increased by 22% with every 1-cm increase in tumor
size.8 The relationship between tumor size and prognosis in pa-
tients with renal cell carcinoma is also conﬁrmed by the tumor
node metastasis staging system, with the 5-year survival rateFig. 2. Engorged renal vein ﬁlled internally with thrombi.decreasing from approximately 80e100% in T1 cases to approxi-
mately 50e80% in T2 cases.9
A large study concluded there were ﬁve important prognostic
factors to predict the survival rate. One of them is the absence of a
prior nephrectomy.10 In addition, the National Comprehensive
Cancer Network guidelines suggest surgical resection as the pri-
mary treatment.11 Surgical resection is an important key procedure
to achieve long-term survival. There are various surgical ap-
proaches when performing a nephrectomy. In this case, we used a
transperitoneal approach because it was easier to control the
pedicle and perform a thrombectomy than with a ﬂank
approach.12,13
To treat metastatic renal cell carcinomas, targeted therapy
instead of immunotherapy is the ﬁrst-line therapy followed by
surgical resection.14 Targeting agents are also superior to immu-
notherapy in prolonging survival.14e18 Several targeting agents,
such as sunitinib, temsirolimus, and sorafenib, have been used to
treat patients with metastatic renal cancer. In clear cell-type renal
cell carcinomas, sunitinib is the ﬁrst choice.19 However, the
response rate to sunitinib is approximately 47%.15 In our case, the
response to sunitinib was not obvious, and this patient had a poor
outcome. Further immunotherapy may have been worth using.Fig. 4. The huge tumor after excision.
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died 6 months after the operation.
A huge renal cell carcinoma is unusual because of the low
growth rate and the development of imaging techniques. In a
literature review, there were several huge renal cell carcinomas.
Ballesteros et al presented a huge renal adenocarcinoma of
5150 g.20 A huge renal tumor was also reported by Wu et al who
found a sarcomatoid renal cell carcinoma, which measured
28 cm.21 Furthermore, one study reported a case of an enormous
chromophobe renal cell carcinoma (with a tumor weight of
11.5 kg).22 The largest reported clear cell renal cell carcinoma was
31  31  10 cm.23
Most of the reported giant renal cancers were of the chromo-
phobe or sarcomatoid type. There were only two case reports of
giant clear cell-type renal cell carcinoma exceeding 20 cm in
diameter.23,24 In this case, we found a huge renal cell carcinoma,
which is very rare. In our experience, with a huge renal cell carci-
noma, the prognosis is very poor even when treated with a radical
nephrectomy and targeted therapy.
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